文献速递颈动脉与弓上血管

右旋糖酐在颈动脉内膜切除术中的辅助作用:系统综述与荟萃分析

Dextran as an Adjunct in Carotid Endarterectomy: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2025-06-27

该系统综述与荟萃分析评估颈动脉内膜切除术(CEA)中应用右旋糖酐患者的血栓栓塞与出血并发症发生率。纳入10项研究共149,540例患者,CEA后30天卒中合并发生率为0.7%(95%CI 0.3-1.1%)。右旋糖酐多选择性用于高危患者,给药方案各异,研究间存在中度异质性,需进一步大规模随机对照试验明确其疗效与安全性。

要点

  • CEA中应用右旋糖酐后30天卒中合并发生率为0.7%(95%CI 0.3-1.1%)。
  • 右旋糖酐主要选择性用于高危患者,各研究给药方案存在差异。
  • 研究间异质性中度(I2=50.79%,P=0.002),地理区域显著贡献异质性(P=0.010)。

核心结论

  • CEA中应用右旋糖酐与低血栓栓塞事件发生率相关。
  • 研究间存在异质性,需进一步大规模随机对照试验明确右旋糖酐的疗效与安全性。
  • 鉴于右旋糖酐潜在出血和肾脏并发症风险,推荐个体化患者选择与标准化给药方案。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Scopus和Web of Science。
  • 纳入10项研究,共149,540例患者,其中9项观察性队列研究(6项回顾性、3项前瞻性)和1项随机对照试验。
  • 采用随机效应荟萃分析估计不良事件合并发生率,通过荟萃回归分析评估异质性。
  • 观察性研究使用美国国家心肺血液研究所研究质量评估工具,随机对照试验使用Cochrane偏倚风险2工具评估质量。

主要发现

  • CEA中应用右旋糖酐后30天卒中合并发生率为0.7%(95%CI 0.3-1.1%),异质性中度(I2=50.79%,P=0.002)。
  • 荟萃回归分析显示地理区域显著贡献异质性(P=0.010)。
  • 糖尿病、高血压和冠状动脉疾病等其他临床协变量与结局变异无显著关联。
  • 右旋糖酐主要选择性用于高危患者,各研究给药方案存在差异。

临床怎么用

  • CEA中右旋糖酐可考虑选择性用于高危患者,但需个体化评估出血和肾脏并发症风险。
  • 建议采用标准化给药方案,并关注地理区域等因素对结局的影响。

局限性

  • 纳入研究以观察性队列为主,仅1项随机对照试验。
  • 研究间存在中度异质性(I2=50.79%),地理区域显著贡献异质性。
  • 右旋糖酐给药方案在各研究间存在差异,多选择性用于高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carotid endarterectomy (CEA) is a widely used surgical procedure to prevent stroke in patients with carotid artery stenosis. Dextran, an antithrombotic agent with antihemostatic properties, has been proposed as an adjunctive therapy to reduce thromboembolic complications during CEA. However, its effectiveness and safety remain controversial. This systematic review and meta-analysis aim to assess the incidence of thromboembolic and hemorrhagic complications in patients undergoing CEA with dextran administration. METHODS: A systematic search was conducted in MEDLINE, Scopus, and Web of Science for studies evaluating the postoperative effects of dextran in CEA patients. Random-effects meta-analysis was performed to estimate the pooled incidence of adverse events, and heterogeneity was assessed through meta-regression analysis. The quality of the included studies was evaluated using the National Heart, Lung, and Blood Institute Study Quality Assessment Tool for observational studies and the Cochrane Risk-of-Bias 2 tool for randomized controlled trials (RCTs). RESULTS: Ten studies, including a total of 149,540 patients, met the inclusion criteria. Of these, 9 were observational cohort studies (6 retrospective and 3 prospective), while one was an RCT. The meta-analytical incidence of stroke following CEA with dextran was 0.7% at 30 days post operatively (95% confidence interval, 0.3-1.1%), with moderate heterogeneity (I2 = 50.79%, P = 0.002). Meta-regression analysis indicated that geographic region significantly contributed to heterogeneity (P = 0.010), while other clinical covariates, such as diabetes, hypertension, and coronary artery disease, were not associated with significant variations in outcomes. Dextran was primarily administered selectively to high-risk patients, with variations in dosing protocols across studies. CONCLUSION: The use of dextran in CEA was associated with a low incidence of thromboembolic events. However, some heterogeneity among studies highlights the need for further large-scale RCTs to clarify its efficacy and safety. Given the potential risks of dextran, including hemorrhage and renal complications, individualized patient selection and standardized administration protocols are recommended.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Silva-Vieira D, Pereira-Neves A, Nzwalo H, et al. Dextran as an Adjunct in Carotid Endarterectomy: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2025. PMID: 40582452. doi:10.1016/j.avsg.2025.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。